Other International projects

IDIBAPS/FCRB also receive funding by other entities from abroad that launch competitive calls for funding. Such entities are usually charities, foundations or private companies.

ANALYSIS OF THE CHROMATIN ACCESIBILITY LANDSCAPE AND REGULATORY NETWORKS OF IgM MONOCLONAL GAMMOPATHIES: TOWARDS A BETTER UNDERSTANDING OF PROGRESSION MECHANISMS

PI: FERNANDEZ DE LARREA RODRIGUEZ, CARLOS JO
Funding: International Waldenstrom's Macroglobulinemia Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: IWMF_SMI_22_01
Amount: 76,805.16 €
Duration: 26/10/2022 to 25/04/2024

TIC Genetics - 1/7-Collaborative Genomics Studies of Tourette Disorder

PI: MORER LIÑAN, ASTRID
Funding: ACADEMISCH ZIEKENHUIS GRONINGEN
Beneficiary organization: FRCB-IDIBAPS
Reference: 671128
Amount: 49,956.31 €
Duration: 15/06/2018 to 30/04/2024

Intra-tumoral heterogeneity and clinical impact in HER2-positive and triple-negative early breast cancer

PI: PRAT APARICIO, ALEIX
Funding: Breast Cancer Research Foundation - BCRF
Beneficiary organization: FRCB-IDIBAPS
Reference: 988310
Amount: 224,596 €
Duration: 01/10/2022 to 30/09/2024

Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

PI: PRAT APARICIO, ALEIX
Funding: Breast Cancer Research Foundation - BCRF
Beneficiary organization: FRCB-IDIBAPS
Reference: BCRF_AAP_01
Amount: 209,086.18 €
Duration: 01/10/2023 to 30/09/2024

In-vitro activity of CD5CAR-NK cells against moulds causing invasive fungal disease

PI: PUERTA ALCALDE, PEDRO
Funding: European Society of Clinical Microbiolog and Infectious Diseases (ESCMID)
Beneficiary organization: FRCB-IDIBAPS
Reference: ESCMID_22_1
Amount: 19,998 €
Duration: 01/04/2023 to 30/09/2024

Efecto del Tratamiento agudo con corticoides endovenosos en las partes blandas en fracturas de pilón tibial, retropié y mediopié en relación con tiempo desde ingreso hasta tratamiento quirúrgico

PI: GARCIA ELVIRA, RUBEN
Funding: AO Foundation AO Global Networks
Beneficiary organization: FRCB-IDIBAPS
Reference: 2021-AOTESASPAIN_003
Amount: 7,254.75 €
Duration: 15/01/2022 to 30/10/2024

Multicentre assessment of nasal swabbing approach: alpha-syn RT QuIC assay diagnostic performance inolfactory mucosa and cerebrospinal fluid in patients with prodromal PD, PD or PD with neurocognitive impairment

PI: MARTI DOMENECH, MARIA JOSEFA
Funding: UNIVERSITA DEGLI STUDI DI VERONA
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-021307
Amount: 100,322.37 €
Duration: 01/04/2022 to 30/11/2024

Identifying New Therapeutic Targets in Obesity-Driven Liver Cancer

PI: FERNANDEZ LOBATO, MERCEDES
Funding: INSTITUT RECERCA BIOMEDICA BARCELONA (IRB)
Beneficiary organization: FRCB-IDIBAPS
Reference: 1766
Amount: 136,893 €
Duration: 01/01/2021 to 31/12/2024

Deciphering the mechanism underlying ECP-induced immunomodulation in kidney transplantation

PI: ROVIRA JUAREZ, JORDI
Funding: European Society for Organ Transplantation
Beneficiary organization: FRCB-IDIBAPS
Reference: ESOT_ECP_23_01
Amount: 50,000 €
Duration: 01/01/2024 to 31/12/2024

Fetal doppler for antenatal risk stratification.

PI: BIJNENS, BART
Funding: AGA KHAN UNIVERSITY
Beneficiary organization: FRCB-IDIBAPS
Reference: INV-021528
Amount: 566,436 €
Duration: 01/01/2021 to 31/12/2024

Phospho-proteome analysis of PBMCs in LRRK2 mutations carriers: expansion & validation of findings of the Barcelona LRRK2 Biorepository

PI: FERNANDEZ SANTIAGO, RUBEN
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-000858
Amount: 77,928.07 €
Duration: 01/08/2021 to 31/12/2024

PPMI - Parkinson's Progression Markers Initiative (PPMI) study

PI: ALDECOA ANSORREGUI, IBAN
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-024484
Amount: 52,683.78 €
Duration: 01/01/2021 to 31/12/2024

What works and why? Eye movement desensitization and reprocessing a potential treatment for substance use disorders

PI: MIQUEL DE MONTAGUT, LAIA
Funding: EMDR Foundation Eye Movement Desensitization & reprocess
Beneficiary organization: FRCB-IDIBAPS
Reference: 2022-02
Amount: 9,000 €
Duration: 01/04/2023 to 31/03/2025

Effectivenessof an EMDR intervention for the prevention of post-traumatic symptoms in perinatal loss

PI: TORRES GIMENEZ, ANNA
Funding: EMDR Foundation Eye Movement Desensitization & reprocess
Beneficiary organization: FRCB-IDIBAPS
Reference: 2022-03
Amount: 7,500 €
Duration: 01/04/2023 to 31/03/2025

HeBA - Barcelona 2022 PPMI Healthy Brain Aging Initiative

PI: MARTI DOMENECH, MARIA JOSEFA
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-022187
Amount: 968,050.79 €
Duration: 31/05/2022 to 30/05/2025

Dual CD19-CART approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

PI: PEREZ GALAN, PATRICIA
Funding: International Follicular Lymphoma Challenge
Beneficiary organization: FRCB-IDIBAPS
Reference: MILKEN_FLF_22_01
Amount: 385,335.7 €
Duration: 01/12/2022 to 30/06/2025

Effects of circulating extracellular vesicles on pancreatic islets during obesity

PI: SERVITJA DUQUE, JOAN MARC
Funding: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Beneficiary organization: FRCB-IDIBAPS
Reference: EFSD/BOEHR_22_01
Amount: 100,000 €
Duration: 09/01/2023 to 08/07/2025

MOLECULAR MEASURABLE RESIDUAL DISEASE (MRD) MONITORING BY HIGH-THROUGHPUT TECHNIQUES IN PATIENTS TREATED WITH CART19 THERAPY

PI: LOPEZ GUERRA, MONICA
Funding: Thermo fisher scientific inc.
Beneficiary organization: FRCB-IDIBAPS
Reference: THERMOONCOCRG_22_01
Amount: 186,393.29 €
Duration: 28/06/2023 to 31/08/2025

RIBOLARIS-PREDICT - Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

PI: PRAT APARICIO, ALEIX
Funding: Breast Cancer Research Foundation - BCRF
Beneficiary organization: FRCB-IDIBAPS
Reference: BCRF_AAP_24
Amount: 200,213.66 €
Duration: 01/10/2024 to 30/09/2025

Novel biomarkers related to sleep-wake alterations in Alzheimer's disease

PI: FALGAS MARTINEZ, NEUS
Funding: Alzheimer's Association
Beneficiary organization: FRCB-IDIBAPS
Reference: AACSF-21-723056
Amount: 151,178.86 €
Duration: 01/11/2021 to 31/10/2025

Molecular dissection of exosome-mediated bis(monocylglycero)phosphate release in Parkinson's disease-related LRRK2 dysfunction.

PI: FERNANDEZ SANTIAGO, RUBEN
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-023914
Amount: 10,582 €
Duration: 01/11/2023 to 31/10/2025

Early detection of perianal fistulizing disease- Pathophysiology and Imaging

PI: SALAS MARTINEZ, MARIA AZUCENA
Funding: THE LEONA M & HARRY B HELMSLEY CHARITABLE TRUST
Beneficiary organization: FRCB-IDIBAPS
Reference: 2008-04050
Amount: 1,745,753 €
Duration: 25/11/2019 to 24/11/2025

HUNTER: Hepatocellular Carcinoma Expediter Network

PI: LLOVET BAYER, JOSEP MARIA
Funding: Newcastle University Accounts Payable
Beneficiary organization: FRCB-IDIBAPS
Reference: AA_17_03
Duration: 01/11/2018 to 30/11/2025

Psoriasis, a metabolic dysregulation of the innate immune system? Targeting ZEB1 in macrophages as a new therapeutic approach to psoriasis

PI: POSTIGO ANGON, ANTONIO ANDRES
Funding: LEO FOUNDATION
Beneficiary organization: FRCB-IDIBAPS
Reference: LEO_19_01
Amount: 491,478 €
Duration: 01/03/2020 to 31/12/2025

Estudio comparativo biomecánico de dos métodos de osteosíntesis para fracturas de meseta tibial Schatzker tipo I

PI: RENAU CERRILLO, MARINA
Funding: AO Foundation AO Global Networks
Beneficiary organization: FRCB-IDIBAPS
Reference: AOTRAUMA_21_01
Amount: 7,221.89 €
Duration: 31/12/2021 to 31/12/2025

Deciphering the molecular signatures of gestational food cravings as drivers of eating disorders in the offspring

PI: HADDAD TOVOLLI, ROBERTA
Funding: Brain and Behaviour Research Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: BBRF_YI_23
Amount: 64,218 €
Duration: 15/01/2024 to 14/01/2026

A new target for the treatment of acute and chronic itch

PI: Gasull Casanova, Xavier
Funding: LEO FOUNDATION
Beneficiary organization: FRCB-IDIBAPS
Reference: LF-OC-22-001114
Amount: 351,488.65 €
Duration: 01/02/2023 to 31/01/2026

Type 2 inflammation and olfactory loss in chronic rhinosinusitis with nasal polyps: Role of Mepolizumab in olfactory cell neurogenesis

PI: MULLOL MIRET, JOAQUIM
Funding: Glaxosmithkline Research & Development Limited
Beneficiary organization: FRCB-IDIBAPS
Reference: 14859
Amount: 389,318.8 €
Duration: 01/09/2023 to 14/03/2026

Preclinical evaluation of Lilly LRRK2 inhibitors for Parkinson's disease using phosphoproteomic analysis

PI: EZQUERRA TRABALON, MARIO ANTONIO
Funding: LILLY, SAU
Beneficiary organization: FRCB-IDIBAPS
Reference: LILLY_RAP_23_01
Amount: 242,258.79 €
Duration: 19/03/2024 to 18/03/2026

Dissecting the role of the 14q32 region in hepatoblastoma "Hblast14"

PI: SANCHO BRU, PAU
Funding: Worldwide Cancer Research
Beneficiary organization: FRCB-IDIBAPS
Reference: 23-0356
Amount: 245,573.14 €
Duration: 01/04/2023 to 31/03/2026

Dissecting the cellular and molecular atlas of Rheumatoid Arthritis (RA) in sustained remission to identify pathways maintaining Remission and Triggering Flares

PI: CAÑETE CRESPILLO, JUAN DE DIOS
Funding: FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
Beneficiary organization: FRCB-IDIBAPS
Reference: FOREUM_21_02
Amount: 90,000 €
Duration: 01/04/2023 to 31/03/2026

Decoding tanycytic mitochondrial dynamics in nutrient sensing and metabolic health.

PI: CLARET CARLES, MARC
Funding: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Beneficiary organization: FRCB-IDIBAPS
Reference: EFSD/LILLY_23_01
Amount: 100,000 €
Duration: 01/07/2024 to 30/06/2026

ATLAX - Characterizing the signals from adipo-liver axis in NASH and unveiling their utility as disease biomarkers.

PI: GRAUPERA GARCIA MILA, ISABEL
Funding: PFIZER INC.
Beneficiary organization: FRCB-IDIBAPS
Reference: PFIZER_NASH_A_22_1
Amount: 127,775.17 €
Duration: 08/11/2023 to 30/06/2026

Mutimodal single cell profiling of tumor cell and microenvironment interactions driving clinical evolution and therapeutic responses in Mantle Cell Lymphoma

PI: CAMPO GUERRI, ELIAS
Funding: ASTRAZENECA UK LTD.
Beneficiary organization: FRCB-IDIBAPS
Reference: ASTRAZ_HEMAT_22_1
Amount: 647,255.72 €
Duration: 04/08/2022 to 03/08/2026

EHIN - Epithelioid Hemangioendothelioma International Network.

PI: RIMOLA GIBERT, JORDI
Funding: EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Beneficiary organization: FRCB-IDIBAPS
Reference: EASL_RG_21_01
Amount: 50,000 €
Duration: 01/09/2021 to 31/08/2026

Transcriptomic impact of blocking IL-5 with mepolizumab on CD4+T lymphocytes from patients with EGPA. Search for predictors of response

PI: ESPIGOL FRIGOLE, GEORGINA
Funding: Glaxosmithkline Research & Development Limited
Beneficiary organization: FRCB-IDIBAPS
Reference: 219739
Amount: 164,895.2 €
Duration: 08/09/2023 to 26/02/2027

MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)

PI: BEA BOBET, SILVIA MARGARITA
Funding: Ludwig-Maximilians-Universitaet Muenchen
Beneficiary organization: FRCB-IDIBAPS
Reference: LLS_MCL_22_2
Amount: 221,720 €
Duration: 01/07/2023 to 30/06/2027

BioRTC Computational Neuroscience Course

PI: COMPTE BRAQUETS, ALBERT
Funding: Simons Foundation
Beneficiary organization: FRCB-IDIBAPS
Reference: 00009921
Amount: 71,009.28 €
Duration: 01/09/2024 to 31/08/2027

Unravelling the functional role and therapeutic potential of transcription factors in chronic lymphocytic leukemia

PI: MAIQUES DIAZ, ALBA
Funding: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Beneficiary organization: FRCB-IDIBAPS
Reference: RG-202310-04245
Amount: 239,281 €
Duration: 01/09/2024 to 31/08/2027

CARTALLEU - Phase 2 clinical trial to evaluate the efficacy and safety of varnimcabtagene autoleucel for relapsed/refractory adult acute lymphoblastic leukaemia

PI: DELGADO GONZÁLEZ, JULIO
Funding: FUNDACIÓN CIENTIFICA ASOCIACIÓN ESPAÑOLA CONTRA EL CANCER
Beneficiary organization: FRCB-IDIBAPS
Reference: ATTRACT_23_01
Duration: 01/04/2024 to 31/03/2029

Structural heart disease training Fellowship

PI: FREIXA ROFASTES, XAVIER
Funding: EDWARDS LIFESCIENCES
Beneficiary organization: FRCB-IDIBAPS
Reference: EDWARDSFELLOW_24_01
Amount: 18,000 €
Duration: 23/07/2024 to 31/12/9998

DIGITALLY-ENHANCED PERSONALIZED MEDICINE: ACCURATE SELECTION OF SUBJECTIVE COGNITIVE DECLINE AND MEASURING PROGRESSION OF MILD COGNITIVE IMPAIRMENT

PI: BALASA, MIRCEA
Funding: ALTOIDA, INC.
Beneficiary organization: FRCB-IDIBAPS
Reference: ADDF_2019_01
Amount: 113,500 €
Duration: 01/08/2021 to 28/02/2024

ToIDC - Impact of autologous tolerogenic dendritic cells (ToIDC) on full mismatch kidney transplantation rat model

PI: VENTURA ABREU AGUIAR, PEDRO
Funding: PORTUGUESE TRANSPLANTATION SOCIETY
Beneficiary organization: FRCB-IDIBAPS
Reference: SPT_BAMPS_19_01
Amount: 10,000 €
Duration: 01/10/2021 to 31/03/2024

CRCNS US-Spanish Research Proposal: Circuit mechanisms of priors and learning during decision making

PI: POL SOROLLA, ALBERTO
Funding: Massachussets Institute of Technology
Beneficiary organization: FRCB-IDIBAPS
Reference: NSF_CRCNS_21_01
Amount: 0.01 €
Duration: 01/12/2022 to 30/11/2025

Modelling Age-related Macular Degeneration with a Blood-Retinal-Barrier Biomimetic System Combining Human Pluripotent Stem Cells and Decellularized Retinal Tissue

PI: MOLINS MONTEY, BLANCA
Funding: NOVARTIS FARMACÉUTICA, S.A
Beneficiary organization: FRCB-IDIBAPS
Reference: NOVARTIS_IIT_21_01
Amount: 37,000 €
Duration: 08/06/2022 to 31/08/2025

INTREPIBD - Identifying digital biomarkers of illNess activity and Treatment REsPonse In Bipolar Disorder .

PI: HIDALGO MAZZEI, DIEGO ALBERTO
Funding: Milken Institute. .
Beneficiary organization: FRCB-IDIBAPS
Reference: MILKEN_BD_21_01
Amount: 151,401.9 €
Duration: 10/12/2021 to 31/08/2024

Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma

PI: CAMPO GUERRI, ELIAS
Funding: Mayo Clinic Arizona
Beneficiary organization: FRCB-IDIBAPS
Reference: NIH_PAR-16-457_01
Amount: 837,653.95 €
Duration: 19/09/2018 to 30/06/2024

European Registry of patients treated with TIPS following a standardized, state of the art, pre, peri and post procedural approach: The EUROTIPS project

PI: RIMOLA GIBERT, JORDI PRAT APARICIO, ALEIX
Funding: EASL, European Association for Study of the Liver
Beneficiary organization: FRCB-IDIBAPS
Reference: EASL_RG_19_01
Amount: 40,000 €
Duration: 20/07/2020 to 19/07/2024

Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes

PI: BEA BOBET, SILVIA MARGARITA
Funding: Ludwig-Maximilians-Universitaet Muenchen
Beneficiary organization: FRCB-IDIBAPS
Reference: LMUM_EMCLP_21_01
Amount: 5,000 €
Duration: 29/04/2022 to 28/04/2024

Tracking the origin of chronic lymphocytic leukemia progression and transformation through its genomic and transcriptonic footprints

PI: CAMPO GUERRI, ELIAS
Funding: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Beneficiary organization: FRCB-IDIBAPS
Reference: RG-202012-00245
Amount: 150,000 €
Duration: 01/01/2022 to 31/12/2024

Molecular characterization of obesity/diabetes/NASH-related hepatocellular carcinoma

PI: LLOVET BAYER, JOSEP MARIA
Funding: EASL, European Association for Study of the Liver
Beneficiary organization: FRCB-IDIBAPS
Reference: EASL_JR_12_20
Amount: 120,000 €
Duration: 01/05/2021 to 30/04/2024

The Edmond J. Safra Fellowship in Movement Disorders - Hospital Clinic Barcelona

PI: CAMPO GUERRI, ELIAS & VALLDEORIOLA SERRA, FRANCESC
Funding: Michael J. Fox Foundation for Parkinson
Beneficiary organization: FRCB-IDIBAPS
Reference: MJFF-023487
Amount: 170,928 €
Duration: 01/09/2023 to 31/08/2026

BLOOD a-SYNUCLEIN AGGREGATION ASSAY AS A NOVEL DIAGNOSTIC TOOL FOR PARKINSON’S DISEASE

PI: FERNANDEZ SANTIAGO, RUBEN & COMPTA HIRNYJ, YAROSLAU
Funding: US Department of Defence
Beneficiary organization: FRCB-IDIBAPS
Reference: DOD_PRP_23_01
Amount: 328,679.43 €
Duration: 01/09/2024 to 31/08/2026

Interaction between MRI metrics and biomarkers of chronic activity to predict disability outcomes and treatment response in multiple sclerosis

PI: LLUFRIU DURAN, SARA
Funding: Congrex Switzerland Ltd,
Beneficiary organization: FRCB-IDIBAPS
Reference: ECTRIMS_FELLOW21_02
Amount: 110,000 €
Duration: 01/11/2022 to 31/10/2024